Drugs / LM11A-31
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07264283 | Jun 2026 → Sep 2030 expected | progressive supranuclear palsy | Adam Boxer | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07173803 | Jun 2026 → Sep 2030 expected | progressive supranuclear palsy | Adam Boxer | Not yet recruiting | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT03069014 Comparator | Feb 2017 → Jun 2020 | — | PharmatrophiX Inc. | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LM11A-31 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03069014 ↗ |
| Action | Inhibit | “treatment with p75NTR inhibitor LM11A-31” PMID 38029807 ↗ Nov 2023 |
| Modality | Small molecule | “first-in-class small molecule LM11A-31” PMID 38760589 ↗ May 2024 |
| Route | Oral | “administered twice daily by oral capsules.” PMID 38760589 ↗ May 2024 |